Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock
August 01, 2013 at 12:09 PM EDT
Shares of Omeros's (NASDAQ: OMER ) traded up as much as 6 percent Thursday morning after the company's announcement of an NDA submission for its intraocular lens replacement surgery treatment OMS302. The stock charged to a session high of $6.19 (up 15 percent) heading into the last hour of the
